New Stem Cell Web Site to Focus on Traumatic Brain Injury, Spinal Cord Injury and Diabetes

SAN DIEGO, May 28 /PRNewswire/ — Entest BioMedical, Inc., a newly formed wholly-owned subsidiary of San Diego-based Bio-Matrix Scientific Group, Inc. (OTCBulletinBoard: BMSN) announced today the launch of its Web site (http://www.EntestBio.com) to focus on new stem cell research, including a proposed research to develop a new therapeutic solution for traumatic brain injury (TBI) using autologous adipose-derived (fat) stem cells representing a potential cure. There are currently 1.5 million new cases of TBI occurring in the U.S. each year, adding to the almost 6.5 million existing cases. The Company is also pursuing research in the use of fat stem cell therapy for spinal cord injury, in which approximately 200,000 patients in the U.S. suffer from this disability.

The site also highlights the Company’s progress in developing a gestational diabetes screening test, as the exclusive licensee granted by UCLA. The non-invasive, highly accurate streamline test mitigates the lengthy process of diagnoses and would more quickly treat the glucose intolerant disease, which potentially impacts 4.3 million pregnant women each year.

Along with background about types of stem cells and factoids, the new site also reviews Entest BioMedical’s focus on the promising field of in vitro expansion of adult stem cells using other types of cells, such as peripheral stem cells and cord blood stem cells to treat cancer and other diseases. The R & D company is also exploring isolating hematopoietic stem cells from peripheral blood or bone marrow and differentiating them into immune cells, especially T cells.

“Our new Web site demonstrates Entest BioMedical’s mission and key scientific personnel who are dedicated to discovering and developing new procedures, treatments and medical devices that improve the quality of life – leading research and technology that serve the present and help shape the future,” said David Koos, Ph.D., DBA, Chairman and CEO.

 http://sev.prnewswire.com/medical-pharmaceuticals/20090528/LA2353228052009-1.html

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: